Articles related to GUIDELINES/RECOMMENDATIONS

The Infectious Diseases Society of America (IDSA) has issued guidance on managing drug interactions with nirmatrelvir/ritonavir (Paxlovid). Specifically, the IDSA recommends clinicians take six steps to minimize the risk of drug interactions for patients with COVID-19 who are eligible for nirmatrelvir/ritonavir.

There haven’t been any national guidelines developed for managing patients with stage 1 hypertension who don’t respond to lifestyle modification. This population represents an important guideline gap: most patients with stage 1 hypertension progress to stage 2 hypertension, which increases the risk for cardiovascular events. The AHA has published a scientific statement to fill the gap – if lifestyle modification fails to reduce blood pressure, consider pharmacotherapy.

A literature review involving 24 recent studies yielded an update to ASCO’s recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.

“The guideline was never intended to set a standard of care in the treatment of pain, much less was it intended to serve as a means to criminally prosecute clinicians. While the new guideline is a substantial improvement, harm from the 2016 guideline will not be easily erased and will require more specific wording than is currently present.” (Requires free registration / login)

CVD is the leading cause of death in the US, accounting for more than one in four deaths. Following a systematic review, the US Preventive Services Task Force has provided an update on the effectiveness of aspirin to reduce the risk of CVD events.

New guidelines recommend that internists treat uncomplicated diverticulitis in an outpatient setting without the use of antibiotics. The new guidelines on diagnosis and management of patients with diverticulitis have been published by the Annals of Internal Medicine. And they are stirring up debate among physicians.